IDEXX Shorts Rebuild Quietly as Earnings Loom

IDXX enters its Monday earnings report with short sellers adding to positions at the margin, while options positioning has turned more defensive than at any point in the past six months.

Short interest has edged up about 1.9% over the past week to roughly 2.4% of the free float, a low absolute level but the highest it has been since mid-September, when shorts were closer to 2.6%. The week's build follows a month in which short interest had been falling. It is a modest repositioning rather than a structural bear thesis. The borrow market reinforces that read: availability remains extraordinarily loose at around 4,470%, meaning shares available to borrow outnumber those already borrowed by more than 40 to one. Cost to borrow doubled over the week to 0.55%, but the starting point was so low that the absolute level is still negligible. Shorts are not in control of this stock.

Options tell the more active story. The put/call ratio moved to 0.58 on Friday, about 1.5 standard deviations above its 20-day average of 0.46. Demand for downside protection has been building consistently since mid-October, when the ratio was near its 52-week low of 0.35. That shift happened as IDXX fell 4.3% in a single session on Friday to $551.21, a sharper move than most of its closest peers. GMED fell 5.9% on the day and MMSI dropped 7.7%, so the broader medical devices space was under pressure. But IDXX's weekly decline of 1.6% was shallower than the peer median of around 3.1%, suggesting some relative resilience even as options buyers are paying up for protection.

The Street's view has been drifting more cautious. UBS trimmed its target from $670 to $627 on October 27, maintaining a Neutral rating. JP Morgan lowered its target from $775 to $750 earlier in October, holding an Overweight. BTIG suspended coverage on Friday. The consensus mean target of $694 implies roughly 26% upside from current levels, but the direction of recent revisions is downward. The ORTEX factor scores are not alarming: EPS surprise ranks in the 70th percentile, reflecting a track record of beating estimates, while forward EPS growth ranks in the 26th percentile, the weakest part of the profile. The P/E is running at about 35x and EV/EBITDA near 25x, valuations that leave little room for a miss.

Retail attention has been elevated too. Wikipedia pageviews for IDEXX carried a z-score of 2.3 as of October 19, well above its own 90-day baseline, a measure of how much attention the name is drawing relative to its own recent history. That kind of elevated interest ahead of a print often reflects investors doing fresh work on the name rather than any directional signal.

Earnings are due Monday. The recent reaction history shows the stock moved down 3.4% on the day after the August 2026 print, and fell another 4.3% over the following five days. The prior quarter produced a modest 1-day gain but a 6.6% decline over the next five days. The pattern of muted initial reactions giving way to extended selling is worth carrying into Monday's session.